TrialsgrambetaRCTs are beautiful

KEYNOTE-522

2020

Pembrolizumab + Chemotherapy in Early Triple-Negative Breast Cancer

In 1,174 patients with stage II–III triple-negative breast cancer, neoadjuvant pembrolizumab + platinum/taxane → AC, then adjuvant pembrolizumab improved pathologic complete response and event-free survival compared with placebo + chemotherapy.

Result

Efficacy: pCR and EFS (co-primary)HR 0.63

Below 1 favours neoadjuvant pembrolizumab + platinum/taxane → AC, then adjuvant pembrolizumab, above 1 favours placebo + chemotherapy.

Event rates
Absolute difference
9.0 points

The absolute difference is derived from the event rates.

Also reported: pCR 64.8% vs 51.2%. 5-yr OS HR 0.66.

Original publication
Subtopic
TNBC neoadjuvant
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Schmid P, et al. N Engl J Med. 2020;382(9):810-821; Schmid P, et al. N Engl J Med. 2022;386(6):556-567.doi 10.1056/NEJMoa1910549

Discussion & critique

Established the first immunotherapy-containing (neo)adjuvant regimen in early TNBC. Long-term immune-related toxicity is a real cost in a curative-intent setting.